Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double‐positive lung cancer
暂无分享，去创建一个
M. Ando | Y. Hasegawa | S. Yano | H. Murakami | Toshiaki Takahashi | K. Fukuda | S. Takeuchi | N. Katakami | K. Yoshimura | A. Hata | S. Shimizu | S. Arai | T. Ko | T. Fujiwara | Azusa Tanimoto | S. Ong | T. Hase | A. Nishiyama | Katsuhiko Nagase | Takahiro Kawakami | S. Tiong Ong